New injection may better prevent chemo sickness in large trial

NCT ID NCT02106494

Completed Symptom relief Sponsor: Heron Therapeutics Source: ClinicalTrials.gov ↗

First seen Mar 04, 2026 · Last updated May 22, 2026 · Updated 5 times

Summary

This study tested a new drug, APF530, against a standard drug, ondansetron, to see which better prevents nausea and vomiting in cancer patients receiving strong chemotherapy. About 942 adults with cancer took part. The goal was to see if APF530 could keep patients from vomiting or needing rescue medicine for more than 24 hours after chemo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Arizona Oncology Associates, PC-HAL

Phoenix, Arizona, 85016, United States
Compassionate Cancer Medical Center

Riverside, California, 92501, United States
Gabrail Cancer Center Research

Canton, Ohio, 44718, United States
North Shore Oncology

East Setauket, New York, 11733, United States
Northern Indiana Research

Mishawaka, Indiana, 46545, United States
Northern Indiana Research

South Bend, Indiana, 46804, United States
The Oncology Institute of Hope and Innovation

Downey, California, 90241, United States

Conditions

Explore the condition pages connected to this study.

CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING